Insider buying last 90 days
No open-market insider purchases were filed for CGON in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
CG Oncology moved sharply this week after its third-quarter results, which showed revenue of $1.6 million, beating a consensus of $1.08 million, alongside a narrower-than-expected per-share loss relative to some estimates, even as reported EPS of ($0.64) missed by $0.04 against another estimate. The quarter's net loss widened to $56.9 million from $43.8 million a year earlier, with a nine-month net loss of $196.1 million, though the company holds $984.5 million in cash, cash equivalents and marketable securities. Coverage also pointed to positive updates on the company's late-stage bladder cancer programs, including cretostimogene grenadenorepvec, which helped support the stock's reaction.
CGON closed at $74.74, down 1.6% on the day, but remains above both its 50-day average of $68.24 and its 200-day average of $66.30, with the 50-day above the 200-day. The GekkoIndex reads 44.1, placing the stock in the Distribution zone, down 20 points over five sessions. Shares trade 3.4% below Gekko Fair Value of $77.38, within the 52-week range of $35.80 to $80.97.
The next earnings date falls on 26 February 2027, 108 days out, outside a typical 20-trading-day hold. No insider, Congress or unusual options activity appears in the current windows. Analyst coverage from 7 firms is unanimously rated buy, with a consensus target of $91.08, implying 21.9% upside. A filing shows Candriam S.C.A. trimmed its position by 20% during the period.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
CG Oncology scores 2 supportive, 2 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $74.40 is above the 50-day ($68.04) and 200-day ($66.68) averages, and the 50-day is above the 200-day.
See the chart47.3, Neutral
Reading 47.3 is in the Neutral zone.
See the GekkoIndex3.9% below
Price is within 5% of Gekko Fair Value (3.9% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 103 days
Next report Feb 26, 2027, 103 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
CG Oncology closed at $74.40 on Nov 13, 2026, +88.8% over the past year, inside a 52-week range of $37.01 to $80.97.
Use the left and right arrow keys to read daily values.
Put CGON on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
CG Oncology is a late-stage clinical biopharmaceutical company focused on treating bladder cancer in the United States. Its work centers on a single investigational therapy, cretostimogene grenadenorepvec, an oncolytic immunotherapy being studied across multiple stages of bladder cancer, including cases where prior BCG treatment has failed and cases considered high risk or intermediate risk.
The company runs a series of clinical programs testing cretostimogene both as a standalone treatment and in different patient groups, including those with BCG-unresponsive disease, papillary tumors, and patients following surgical removal of tumors through TURBT. These programs span phase 2 and phase 3 trials, each designed to examine safety and effectiveness of the therapy in a specific bladder cancer population. As a clinical-stage company, its business is built around advancing this pipeline of trials rather than selling an approved product.
CG Oncology was founded in 2010 under the name Cold Genesys, Inc. and adopted its current name in June 2020. It is headquartered in Irvine, California, and its shares are listed on the NASDAQ under the ticker CGON.
CG Oncology’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.3, in the Neutral zone, up 1 point over five sessions.
Up 1 point over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +4.0% | +16.7% | ||
| Accumulation | 197 | +1.9% | +4.3% | ||
| Neutral (current zone) | 423 | +0.1% | +0.3% | ||
| Distribution | 35 | −0.2% | +4.1% | ||
| Selling | 2 | Too few readings yet | |||
Average CGON share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
CG Oncology trades 3.9% below Gekko Fair Value of $77.41, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what CG Oncology shares are worth, recalculated every trading day.
$77.41
Gekko Fair Value, Nov 14, 2026
3.9% below fair value · About fair value
At the end of Aug 2026 the price was 12.2% below the estimate.
No open-market insider purchases were filed for CG Oncology, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CGON in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in CGON were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
2of the funds Gekko tracks hold CGON.
CG Oncology reports on Feb 26, 2027 (103 days away), and beat the EPS estimate in 2 of its last 8 reports.
Feb 26, 2027
103 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.90 est −$0.66 | $1.16M est $361K | +3.7% |
| May 8, 2026 | −$0.71 est −$0.58 | $1.08M est $453K | +0.2% |
| Feb 27, 2026 | −$0.51 est −$0.61 | $2.30M est $451K | +2.9% |
| Nov 14, 2025 | −$0.57 est −$0.56 | $1.67M est $59K | +9.2% |
| Aug 8, 2025 | −$0.54 est −$0.49 | — est $82K | −1.6% |
| May 13, 2025 | −$0.45 est −$0.39 | $52K est $118K | −3.9% |
| Mar 28, 2025 | −$0.48 est −$0.41 | $456K est $124K | −9.1% |
| Nov 14, 2024 | −$0.30 est −$0.42 | — | −6.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for CG Oncology is $91.46, +22.9% from the last close, from 7 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 7 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $102 | +37.1% |
| Nov 9 | Wedbush | $84 | +12.9% |
| Nov 9 | Guggenheim | $89 | +19.6% |
| Nov 6 | JonesTrading | $85 | +14.2% |
| Nov 6 | H.C. Wainwright | $100 | +34.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
CG Oncology’s market cap is $6.65B and revenue of $6.17M over the last twelve months.
Coverage of CG Oncology this week reads positive: 4 positive, 1 neutral and 2 negative headlines.
CG Oncology’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
CG Oncology’s market cap is $6.65B at the Nov 13, 2026 close of $74.40, with 89.32M shares outstanding.
The consensus analyst 12-month price target for CG Oncology is $91.46, +22.9% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate CG Oncology is about fair value: the Nov 13, 2026 close of $74.40 is 3.9% below Gekko Fair Value of $77.41. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
CG Oncology is expected to report on Feb 26, 2027 (103 days away). Analysts expect earnings of −$0.71 per share on revenue of $886K. CG Oncology beat the earnings estimate in 2 of its last 8 reports, moving 4.6% on average across the report.
CG Oncology’s 52-week high is $80.97 and its 52-week low is $37.01; it closed at $74.40 on Nov 13, 2026, +88.8% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.